Following Astrazeneca plc's decision to return fostamatinib rights to Rigel Pharmaceuticals Inc. last year, Rigel is pushing ahead with twin phase III studies of the oral spleen tyrosine kinase (SYK) inhibitor in patients with the tough-to-beat bleeding disorder, immune thrombocytopenic purpura (ITP).